National Institutes of Health: Urethral Neoplasms trials

The registry lists 18 Urethral Neoplasms studies with National Institutes of Health as lead sponsor. 1 are open to participants now and 7 have results posted.

Phase 1 4Phase 2 12Phase 3 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsRecruitingNCT03866382Phase 2
• Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial CarcinomaCompletedNCT03513952Phase 2Results posted
• Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by SurgeryCompletedNCT02178241Phase 2Results posted
• Cabozantinib for Advanced Urothelial CancerCompletedNCT01688999Phase 2Results posted
• Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract CancerCompletedNCT00942331Phase 3Results posted
• Pazopanib in Treating Patients With Metastatic Urothelial CancerCompletedNCT00471536Phase 2Results posted
• VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the UrotheliumCompletedNCT00407485Phase 2Results posted
• Sorafenib in Treating Patients With Regional or Metastatic Cancer of the UrotheliumTerminatedNCT00112905Phase 2Results posted
• Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV StudyActive, not recruitingNCT05092958Phase 3
• Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and ImmunotherapyActive, not recruitingNCT04963153Phase 1
• Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial CancerActive, not recruitingNCT03237780Phase 2
• Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary TumorsActive, not recruitingNCT02496208Phase 1
• Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid TumorsCompletedNCT01352962Phase 1
• Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell CarcinomaCompletedNCT00072150Phase 2
• Ixabepilone in Treating Patients With Advanced Urinary Tract CancerCompletedNCT00021099Phase 2
• Arsenic Trioxide in Treating Patients With Urothelial CancerCompletedNCT00009867Phase 2
• Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the UrotheliumTerminatedNCT00004856Phase 2
• Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1